ArticleIndian pediatrics2026
Oral Zinc Supplementation as an Adjunct to Standard Therapy in Children with Steroid-Sensitive Nephrotic Syndrome: A Double-Blind Randomized Controlled Trial.
Article in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A double-blind randomized placebo-controlled trial aimed to evaluate the effect of oral zinc supplementation on reducing relapse frequency in children aged 1-12 years with steroid-sensitive nephrotic syndrome (SSNS). 84 participants were randomized to receive oral zinc (7 mg/day for 1-3 years and 10 mg/day for 4-12 years), or placebo for six months along with standard therapy. Although median (q1, q3) number of relapses during the 6-month study period was similar in zinc and placebo groups [1 (0, 1.5) vs 1 (1, 1); P = 0.575], infection-related relapses were less frequent in the zinc group (57% vs 80%). No significant differences were observed in cumulative steroid-dose, growth or adverse effects. Zinc reduces infection-associated relapses with no overall reduction in relapse rates.Trial Registry CTRI/2021/01/030586.
Indexed as
Identifiers
42622773What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.